Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Nature medicine, Jan 2021 | 27 (2), 256-263

DOI: 10.1038/s41591-020-01211-7

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Rozeman, E A ; Hoefsmit, E P ; Reijers, I L M ; Saw, R P M ; Versluis, J M ; Krijgsman, O ; Dimitriadis, P ; Sikorska, K ; van de Wiel, B A ; Eriksson, H ; Gonzalez, M ; Torres Acosta, A ; Grijpink-Ongering, L G ; Shannon, K ; Haanen, J B A G ; Stretch, J ; Ch'ng, S ; Nieweg, O E ; Mallo, H A ; Adriaansz, S ; Kerkhoven, R M ; Cornelissen, S ; Broeks, A ; Klop, W M C ; Zuur, C L ; van Houdt, W J ; Peeper, D S ; Spillane, A J ; van Akkooi, A C J ; Scolyer, R A ; Schumacher, T N M ; Menzies, A M ; Long, G V ; Blank, C U

PRODUCTS USED

NGS

Read Full Article

ABSTRACT

Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in patients with macroscopic stage III melanoma in the phase 1b OpACIN ( NCT02437279 ) and phase 2 OpACIN-neo ( NCT02977052 ) studies1,2. While the results are promising, data on the durability of these pathologic responses and baseline biomarkers for response and survival were lacking. After a median follow-up of 4 years, none of the patients with a pathologic response (n = 7/9 patients) in the OpACIN study had relapsed. In OpACIN-neo (n = 86), the 2-year estimated relapse-free survival was 84% for all patients, 97% for patients achieving a pathologic response and 36% for nonresponders (P

Read Full Article

PRODUCTS USED

NGS

Genes

Oligo Pools

NGS Target Enrichment Solutions

Variant Libraries

Synthetic Controls

Antibody Discovery